The Cancer Genomic Improvement Programme (CGIP) has been established, and funded by the NHS England Cancer Programme in 24-25, to tackle the end-to-end turnaround times approved for a series of solid tumours and haemato-oncology during 2023. EMCA, working alongside the GMSA, is supporting the CGIP.

The Cancer Genomics Improvement Programme is a critical initiative mandated by NHSE to reduce turnaround times for cancer diagnostics and treatment in our region. Meeting these new targets is essential for improving patient outcomes and ensuring compliance with national standards.

Actions will be taken within each region to improve turnaround times across the end-to-end pathway (from sample acquisition, through cell pathology / haematology, CPGCs and the genomic laboratory, to issue of the report for the treating clinician), with the ultimate aim of delivering the approved turnaround times.